lunes, 29 de abril de 2019

Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. - PubMed - NCBI

2019 Apr 16. pii: clincanres.3663.2018. doi: 10.1158/1078-0432.CCR-18-3663. [Epub ahead of print]

Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.

Coombes RC1, Page K2, Salari R3, Hastings RK2, Armstrong AC4, Ahmed S5, Ali S6, Cleator SJ7, Kenny LM6, Stebbing J8, Rutherford MJ9, Sethi H10, Boydell AR6, Swenerton R3, Fernandez-Garcia D11, Gleason K6, Goddard KS6, Guttery DS11, Assaf Z3, Wu HT3, Natarajan P3, Moore DA12, Primrose L2, Dashner S3, Tin AS3, Balcioglu M10, Srinivasa R10, Shchegrova S3, Olson AG13, Hafez D3, Billings P3, Aleshin A3, Rehman F6, Toghill B11, Hills AH14, Louie MC3, Lin CJ15, Zimmermann BG16, Shaw JA17.

Author information

Abstract

PURPOSE:

Up to 30% of breast cancer patients relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here we demonstrate the use of personalized ctDNA profiling for detection of recurrence in breast cancer.

METHODS:

Forty-nine primary breast cancer patients were recruited following surgery and adjuvant therapy. Plasma samples (n=208) were collected every 6 months for up to 4 years. Personalized assays targeting 16 variants selected from primary tumor whole exome data were tested in serial plasma for the presence of ctDNA by ultra-deep sequencing (average >100,000X).

RESULTS:

Plasma ctDNA was detected ahead of clinical or radiological relapse in 16 of the 18 relapsed patients (sensitivity of 89%); metastatic relapse was predicted with a lead time of up to 2 years (median=8.9 months; range: 0.5-24.0 months). None of the 31 non-relapsing patients were ctDNA-positive at any time point across 156 plasma samples (specificity of 100%). Of the two relapsed patients who were not detected in the study, the first had only a local recurrence, while the second patient had bone recurrence and had completed chemotherapy just 13 days prior to blood sampling.

CONCLUSIONS:

This study demonstrates that patient-specific ctDNA analysis can be a sensitive and specific approach for disease surveillance for breast cancer patients. More importantly, earlier detection of up to two years provides a possible window for therapeutic intervention.